Mofegiline Explained

Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease,^{[1] [2] [3] [4]} but was never marketed.^[5]

See also

• Ladostigil
• Lazabemide
• Rasagiline
• Selegiline

Notes and References

1. Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A . Design and early clinical evaluation of selective inhibitors of monoamine oxidase . Progress in Neuro-psychopharmacology & Biological Psychiatry . 12 . 6 . 967–87 . 1988 . 3266532 . 10.1016/0278-5846(88)90092-9. 32734728 .
2. Zreika M, Fozard JR, Dudley MW, Bey P, McDonald IA, Palfreyman MG . MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease . Journal of Neural Transmission. Parkinson's Disease and Dementia Section . 1 . 4 . 243–54 . 1989 . 2597310 . 10.1007/bf02263478. 26335432 .
3. Book: Palfreyman MG, McDonald IA, Bey P, Danzin C, Zreika M, Cremer G . Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential . Amine Oxidases: Function and Dysfunction . Journal of Neural Transmission. Supplementum . 41 . 407–14 . 1994 . 7931257 . 10.1007/978-3-7091-9324-2_54. 978-3-211-82521-1 .
4. Thiffault C, Quirion R, Poirier J . Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain . Synapse . 28 . 3 . 208–11 . March 1998 . 9488505 . 10.1002/(SICI)1098-2396(199803)28:3<208::AID-SYN3>3.0.CO;2-E . 20976168 .
5. Book: Ganellin CR, Triggle DJ, Macdonald F . Dictionary of pharmacological agents . 25 November 2011 . 1997 . CRC Press . 978-0-412-46630-4 . 1370 .